Carolyn Millar is a Senior Lecturer in the department of haematology and a Consultant Haematologist specialising in haemostasis and thrombosis. She is the clinical lead in haemophilia at the Hammersmith hospital. Dr Millar completed undergraduate medical training at the University of Newcastle-upon-Tyne, graduating with honours. She undertook postgraduate medical training at University College London, the National Hospital for Neurology & Neurosurgery, Queen Square, and St George’s Hospital, Tooting. Dr Millar’s haematology training was largely undertaken at the Hammersmith, Great Ormond Street and Royal Free hospitals, where her doctoral thesis investigated the role of glycans in von Willebrand factor clearance and their relation to von Willebrand disease. Dr Millar has continued to study the configuration, function and kinetics of von Willebrand factor since being awarded a HEFCE clinical senior lectureship to start her position at Imperial College in December 2008 . As well as von Willebrand disease, her clinical interests include obstetric haemostasis, rare bleeding disorders, haemophilia and anticoagulant therapy. Dr Millar has led on the UK surveillance of vCJD in patients with bleeding disorders since 2002.
Dr Millar supervises postdoctoral research fellows and MSc., BSc., MD and PhD students and holds a variety of leadership and senior teaching positions at Imperial College. Between 2012 and 2019 she was course co-director of the intercalated BSc programme in haematology and is now head of assessment. Dr Millar is haematology lead for Phase I of the new curriculum and personal tutor to MBBS students in years 3-6.. Dr Millar obtained a diploma in undergraduate teaching in 2012 and in 2013 was awarded an Imperial College Teaching Excellence award
et al., 2019, Inherited missense variants that affect GFI1B function do not necessarily cause bleeding diatheses, Haematologica, Vol:104, ISSN:0390-6078, Pages:E260-E264
et al., 2019, Germline selection shapes human mitochondrial DNA diversity, Science, Vol:364, ISSN:0036-8075
et al., 2017, A common mechanism by which type 2A von Willebrand Disease mutations enhance ADAMTS13 proteolysis revealed with a von Willebrand Factor A2 domain FRET construct, Plos One, Vol:12, ISSN:1932-6203
et al., 2017, Expanded repertoire of RASGRP2 variants responsible for platelet dysfunction and severe bleeding, Blood, Vol:130, ISSN:1528-0020, Pages:1026-1030
Millar CM, Laffan MA, 2017, Corrigendum: Drug therapy in anticoagulation: which drug for which patient?, Clinical Medicine, Vol:17, ISSN:1470-2118, Pages:347-349